Allows for quick analysis of the pipeline
and a high-level estimate of the peak share potential of new products.
Designed for the US market, this tool will help you generate an expected Gross-to-Net result for your specific product.
Work your way through the mechanisms to see if or to what degree the IRA will impact on your future product pricing and strategy.
Developed to enable the evaluation of market access potential, and its impact on investment decisions and NPV valuations.
A tool designed to deliver peak share estimates that could directly be used for high level forecasting, but could also be used to complement, challenge, or refine forecast assumptions derived from other approaches.
A tool to allow for a quick high level estimation of a reasonable price for a new treatment in the US at the Gross and the Net level. The present tool aims to deliver a view on the Gross pricing of key current treatments in selected key indications.
